Table S1 ) were immunized with 3 doses of prototype-Beta chimeric RBD-dimer vaccine or sham (n = 12), 21 days apart. Serum samples were collected according to the study schedule shown in
Figure S5 B. (A) Endpoint titer of antigen-binding IgG. (B) 50% neutralization titer of pseudotyped virus (prototype, Alpha, Beta, Delta, and Omicron) in serum. (C) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Alpha, Beta, and Delta). (D) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Beta and Omicron). The values shown in (A)–(D) are the GMT ± 95% confidence interval (CI). (E) Summed IFN-γ, IL-2 and IL-4 ELISPOT responses in PBMCs collected at day 6 after the third dose toward peptides spanning SARS-CoV-2 RBD. The values are means ± SEM. p values were analyzed with two-tailed Mann-Whitney test. ( ∗∗ p < 0.01; ∗∗∗ p <0.001; ∗∗∗∗ p < 0.0001). " width="100%" height="100%">
Journal: Cell
Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
doi: 10.1016/j.cell.2022.04.029
Figure Lengend Snippet: Immunogenicity of prototype-Beta chimeric vaccine in rhesus macaques Twenty-four rhesus macaques (see Table S1 ) were immunized with 3 doses of prototype-Beta chimeric RBD-dimer vaccine or sham (n = 12), 21 days apart. Serum samples were collected according to the study schedule shown in Figure S5 B. (A) Endpoint titer of antigen-binding IgG. (B) 50% neutralization titer of pseudotyped virus (prototype, Alpha, Beta, Delta, and Omicron) in serum. (C) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Alpha, Beta, and Delta). (D) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Beta and Omicron). The values shown in (A)–(D) are the GMT ± 95% confidence interval (CI). (E) Summed IFN-γ, IL-2 and IL-4 ELISPOT responses in PBMCs collected at day 6 after the third dose toward peptides spanning SARS-CoV-2 RBD. The values are means ± SEM. p values were analyzed with two-tailed Mann-Whitney test. ( ∗∗ p < 0.01; ∗∗∗ p <0.001; ∗∗∗∗ p < 0.0001).
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat#3410-2APW-10.
Techniques: Immunopeptidomics, Binding Assay, Neutralization, Virus, Enzyme-linked Immunospot, Two Tailed Test, MANN-WHITNEY
Journal: Cell
Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
doi: 10.1016/j.cell.2022.04.029
Figure Lengend Snippet:
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat#3410-2APW-10.
Techniques: Virus, Isolation, Infection, Variant Assay, Recombinant, Adjuvant, Enzyme-linked Immunospot, Software, Microscopy
Journal: medRxiv
Article Title: Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children
doi: 10.1101/2022.03.03.22271313
Figure Lengend Snippet: IFN-γ- and IL-4-secreting cells in peripheral blood mononuclear cells stimulated with RBD. Children 3-11 (N=24) and 12-18 years old (N=21) received two doses (on days 0, 28) of SOBERANA 02 and a heterologous third dose (on day 56) of SOBERANA Plus. p value represents the statistic differences as indicated.
Article Snippet: RBD-specific T-cell response producing IFN-γ and IL-4 were quantified by enzyme-linked immunospot (ELISpot) assay using human IFN-γ ELISpot PLUS HRP kit (Mabtech, Sweden) and human IL-4 ELISpot plus HRP kit (Mabtech, Sweden) following the manufacturer’s instructions.
Techniques:
